New York State Common Retirement Fund Boosts Position in Twist Bioscience Co. (NASDAQ:TWST)

New York State Common Retirement Fund grew its holdings in Twist Bioscience Co. (NASDAQ:TWST) by 5.0% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 370,849 shares of the company’s stock after acquiring an additional 17,715 shares during the period. New York State Common Retirement Fund owned about 0.64% of Twist Bioscience worth $13,669,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in the business. China Universal Asset Management Co. Ltd. boosted its holdings in Twist Bioscience by 96.3% in the third quarter. China Universal Asset Management Co. Ltd. now owns 1,470 shares of the company’s stock valued at $30,000 after purchasing an additional 721 shares during the last quarter. Teacher Retirement System of Texas lifted its holdings in shares of Twist Bioscience by 5.1% in the 3rd quarter. Teacher Retirement System of Texas now owns 16,206 shares of the company’s stock valued at $328,000 after buying an additional 790 shares during the period. Harbor Capital Advisors Inc. boosted its stake in shares of Twist Bioscience by 4.3% in the third quarter. Harbor Capital Advisors Inc. now owns 25,897 shares of the company’s stock worth $525,000 after buying an additional 1,062 shares during the last quarter. Allspring Global Investments Holdings LLC grew its holdings in Twist Bioscience by 51.8% during the third quarter. Allspring Global Investments Holdings LLC now owns 3,453 shares of the company’s stock worth $70,000 after acquiring an additional 1,179 shares during the period. Finally, Federated Hermes Inc. purchased a new position in Twist Bioscience during the third quarter valued at approximately $29,000.

Analysts Set New Price Targets

Several equities research analysts have commented on the company. Scotiabank upped their price objective on Twist Bioscience from $30.00 to $43.00 and gave the stock a “sector outperform” rating in a research report on Monday, February 5th. Barclays dropped their price target on shares of Twist Bioscience from $45.00 to $40.00 and set an “overweight” rating on the stock in a research report on Wednesday, April 10th. Finally, The Goldman Sachs Group raised shares of Twist Bioscience from a “neutral” rating to a “buy” rating and lifted their price objective for the company from $25.00 to $45.00 in a report on Wednesday, January 17th.

Insider Activity at Twist Bioscience

In other Twist Bioscience news, Director Robert Chess sold 4,110 shares of the stock in a transaction that occurred on Thursday, February 8th. The stock was sold at an average price of $34.98, for a total transaction of $143,767.80. Following the completion of the transaction, the director now owns 64,169 shares of the company’s stock, valued at $2,244,631.62. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In related news, Director Robert Chess sold 4,110 shares of the stock in a transaction on Thursday, February 8th. The stock was sold at an average price of $34.98, for a total value of $143,767.80. Following the completion of the transaction, the director now directly owns 64,169 shares of the company’s stock, valued at approximately $2,244,631.62. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, COO Patrick John Finn sold 2,174 shares of the firm’s stock in a transaction on Tuesday, April 23rd. The shares were sold at an average price of $30.12, for a total value of $65,480.88. Following the completion of the transaction, the chief operating officer now owns 176,206 shares in the company, valued at approximately $5,307,324.72. The disclosure for this sale can be found here. In the last three months, insiders have sold 13,211 shares of company stock valued at $449,573. 3.92% of the stock is owned by corporate insiders.

Twist Bioscience Stock Up 1.6 %

Shares of TWST stock opened at $32.03 on Tuesday. Twist Bioscience Co. has a 1-year low of $11.46 and a 1-year high of $43.21. The stock has a 50 day simple moving average of $34.57 and a 200-day simple moving average of $30.57.

Twist Bioscience (NASDAQ:TWST) last posted its quarterly earnings data on Friday, February 2nd. The company reported ($0.75) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.78) by $0.03. Twist Bioscience had a negative net margin of 78.44% and a negative return on equity of 32.16%. The company had revenue of $71.50 million during the quarter, compared to analysts’ expectations of $67.59 million. During the same period in the prior year, the business posted ($0.74) earnings per share. The firm’s revenue for the quarter was up 31.8% on a year-over-year basis. Analysts expect that Twist Bioscience Co. will post -3.17 EPS for the current year.

Twist Bioscience Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.